If WP states in the recent company announcement that new supportive capital will not be dilutive that suggests to me that he will do a TAVR deal which would involve the valve tech independently and not involve the company as such i.e. sell 60% of the TAVR for $35m which would keep us afloat and reduce our future TAVR ongoing costs without dilution. In other words sell a fraction of the company to keep the rest afloat.
Either that or he has a buyer for the infusion business which he will announce soon. I cannot help thinking that the TAVR interest is very costly to keep progressing. IF we sold 75% of this business we might reduce our costs by 50% and become profitable? We could still supply the Adapt material for the TAVR and the 4C valves as well as retaining a percentage interest in the TAVR story. At least we would survive and thrive with a P/E of 40 or more.
- Forums
- ASX - By Stock
- AVR
- Why no announcements
Why no announcements, page-56
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AVR (ASX) to my watchlist
|
|||||
Last
$15.22 |
Change
-0.080(0.52%) |
Mkt cap ! $320.6M |
Open | High | Low | Value | Volume |
$15.10 | $15.30 | $15.02 | $42.48K | 2.807K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 6 | $15.07 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$15.28 | 125 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 6 | 15.080 |
2 | 28 | 15.020 |
1 | 15 | 15.010 |
3 | 727 | 15.000 |
1 | 1000 | 14.850 |
Price($) | Vol. | No. |
---|---|---|
15.280 | 125 | 1 |
15.380 | 541 | 2 |
15.480 | 33 | 1 |
15.570 | 779 | 1 |
15.580 | 34 | 1 |
Last trade - 11.53am 20/08/2024 (20 minute delay) ? |
Featured News
AVR (ASX) Chart |